NEXT STEPS

From aligning your IT with your business needs to an end-to-end strategy for transforming your enterprise, TCS has the world-class experience and expertise that you need. Contact a consultant today.

Email TCS:

Find a TCS location:

    Home > Resources > White Papers > Enterprise Architecture - Fundamental to the Overall Transformation of a Pharmaceutical Company

White Paper

Enterprise Architecture - Fundamental to the Overall Transformation of a Pharmaceutical Company

 

Today’s pharmaceutical industry particularly within the clinical R&D domain faces challenges such as growing market competition, increasingly stringent regulatory environments, rising costs and a collaborative environment.

Partners are leading organizations to embark on a transformation journey affecting people, processes and IT. This process involves huge investments and challenges in terms of budget, time and resource constraints, and as a result the focus is often lost without a clear definition of the guiding Enterprise Architecture (EA).

In this white paper, we demonstrate how an industry standard methodology can be adopted, tailored and extended to create enterprise and specific architecture artifacts. We base this paper on a real-life example in defining enterprise architecture for a clinical R&D unit of a leading pharmaceutical company undergoing a large transformation.

The approach and artifacts described in this paper are intended to aid in EA definition for large transformation programs with a proven, effective, reusable and result-oriented set of architecture views that can be adapted across industries.